Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Illumina Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Net fixed asset turnover 4.24 4.33 3.80 3.51 3.56 3.77 4.00 3.99 3.95 3.99 3.99 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36
Net fixed asset turnover (including operating lease, right-of-use asset) 2.54 2.68 2.41 2.23 2.23 2.33 2.45 2.45 2.42 2.41 2.38 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36
Total asset turnover 0.28 0.46 0.40 0.43 0.44 0.46 0.49 0.48 0.49 0.49 0.46 0.48 0.48 0.53 0.53 0.52 0.51 0.51 0.53 0.56
Equity turnover 0.40 0.77 0.71 0.69 0.69 0.73 0.77 0.77 0.78 0.79 0.85 0.89 0.93 0.95 0.98 1.00 0.91 0.92 0.95 1.09

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Illumina Inc. net fixed asset turnover ratio improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021 not reaching Q1 2021 level.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Illumina Inc. total asset turnover ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Illumina Inc. equity turnover ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.

Net Fixed Asset Turnover

Illumina Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Property and equipment, net 1,009 915 915 922 910 890 890 889 875 854 852 1,075 1,060 1,036 983 931 862 837 734 713 634 511 385
Long-term Activity Ratio
Net fixed asset turnover1 4.24 4.33 3.80 3.51 3.56 3.77 4.00 3.99 3.95 3.99 3.99 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 10.75 10.41 9.67 8.73 8.15 7.38 11.50 11.23
Amgen Inc. 4.89 4.92 4.93 4.96 4.94 4.78 4.68 4.51
Bristol-Myers Squibb Co. 7.75 7.66 7.43 7.22 6.86 6.03 5.07 4.18
Danaher Corp. 7.71 7.84 7.59 6.83 6.68 6.35 6.03 7.78
Eli Lilly & Co. 3.11 3.02 2.95 2.83 2.80 2.88 2.92 2.83
Gilead Sciences Inc. 5.40 5.27 5.06 4.90 4.74 4.70 4.90 4.91
Johnson & Johnson 4.95 4.79 4.59 4.40 4.53 4.57 4.75 4.65
Merck & Co. Inc. 2.57 2.61 2.55 2.67 2.80 2.99 3.15 3.11
Moderna Inc. 12.95 7.72 5.20 0.67 0.00 0.00 0.00 0.00
Pfizer Inc. 4.79 3.89 3.31 3.01 2.98 3.21 3.47 3.71
Regeneron Pharmaceuticals Inc. 3.99 3.69 2.82 2.64 2.63 2.64 2.71 2.72
Thermo Fisher Scientific Inc. 5.54 5.83 5.85 5.45 5.50 5.37 5.42 5.38

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Net fixed asset turnover = (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020) ÷ Property and equipment, net
= (1,108 + 1,126 + 1,093 + 953) ÷ 1,009 = 4.24

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Illumina Inc. net fixed asset turnover ratio improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Illumina Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
 
Property and equipment, net 1,009 915 915 922 910 890 890 889 875 854 852 1,075 1,060 1,036 983 931 862 837 734 713 634 511 385
Operating lease right-of-use assets 676 566 529 532 545 549 559 555 555 558 574
Property and equipment, net (including operating lease, right-of-use asset) 1,685 1,481 1,444 1,454 1,455 1,439 1,449 1,444 1,430 1,412 1,426 1,075 1,060 1,036 983 931 862 837 734 713 634 511 385
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.54 2.68 2.41 2.23 2.23 2.33 2.45 2.45 2.42 2.41 2.38 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Moderna Inc. 11.40 6.83 4.19 0.52 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020) ÷ Property and equipment, net (including operating lease, right-of-use asset)
= (1,108 + 1,126 + 1,093 + 953) ÷ 1,685 = 2.54

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q1 2021 to Q2 2021 but then slightly deteriorated from Q2 2021 to Q3 2021 not reaching Q1 2021 level.

Total Asset Turnover

Illumina Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Total assets 15,063 8,675 8,755 7,585 7,404 7,248 7,261 7,316 7,089 6,973 7,390 6,959 6,759 5,851 5,542 5,257 5,046 4,858 4,598 4,281 4,228 3,985 3,794
Long-term Activity Ratio
Total asset turnover1 0.28 0.46 0.40 0.43 0.44 0.46 0.49 0.48 0.49 0.49 0.46 0.48 0.48 0.53 0.53 0.52 0.51 0.51 0.53 0.56
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.37 0.36 0.33 0.30 0.27 0.24 0.37 0.37
Amgen Inc. 0.37 0.40 0.38 0.39 0.37 0.36 0.37 0.37
Bristol-Myers Squibb Co. 0.41 0.40 0.38 0.36 0.31 0.27 0.24 0.20
Danaher Corp. 0.34 0.34 0.33 0.29 0.28 0.27 0.26 0.29
Eli Lilly & Co. 0.58 0.56 0.54 0.53 0.53 0.55 0.56 0.57
Gilead Sciences Inc. 0.41 0.39 0.37 0.36 0.37 0.39 0.37 0.36
Johnson & Johnson 0.51 0.51 0.49 0.47 0.47 0.51 0.53 0.52
Merck & Co. Inc. 0.51 0.52 0.51 0.52 0.53 0.52 0.57 0.55
Moderna Inc. 0.52 0.38 0.15 0.03 0.00 0.00 0.00 0.00
Pfizer Inc. 0.39 0.33 0.29 0.27 0.24 0.25 0.29 0.31
Regeneron Pharmaceuticals Inc. 0.57 0.58 0.52 0.50 0.51 0.55 0.51 0.53
Thermo Fisher Scientific Inc. 0.53 0.57 0.54 0.47 0.44 0.43 0.44 0.44

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Total asset turnover = (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020) ÷ Total assets
= (1,108 + 1,126 + 1,093 + 953) ÷ 15,063 = 0.28

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Illumina Inc. total asset turnover ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.

Equity Turnover

Illumina Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Total Illumina stockholders’ equity 10,593 5,180 4,922 4,694 4,700 4,563 4,635 4,613 4,439 4,332 3,985 3,758 3,503 3,257 3,008 2,749 2,855 2,715 2,551 2,197 2,240 2,056 1,991
Long-term Activity Ratio
Equity turnover1 0.40 0.77 0.71 0.69 0.69 0.73 0.77 0.77 0.78 0.79 0.85 0.89 0.93 0.95 0.98 1.00 0.91 0.92 0.95 1.09
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 4.07 4.27 3.66 3.50 2.66 2.46
Amgen Inc. 2.96 2.93 2.56 2.58 2.17 2.17 2.41 2.30
Bristol-Myers Squibb Co. 1.22 1.21 1.14 1.12 0.79 0.71 0.62 0.51
Danaher Corp. 0.65 0.62 0.61 0.56 0.54 0.52 0.58 0.59
Eli Lilly & Co. 3.58 4.15 3.69 4.35 4.81 5.61 7.50 8.56
Gilead Sciences Inc. 1.27 1.34 1.33 1.34 1.31 1.21 1.01 0.98
Johnson & Johnson 1.30 1.28 1.28 1.31 1.25 1.28 1.35 1.38
Merck & Co. Inc. 1.33 1.41 1.73 1.90 1.62 1.71 1.83 1.81
Moderna Inc. 1.08 0.91 0.50 0.08 0.00 0.00 0.00 0.00
Pfizer Inc. 0.91 0.79 0.68 0.66 0.66 0.70 0.75 0.82
Regeneron Pharmaceuticals Inc. 0.78 0.82 0.77 0.77 0.81 0.88 0.66 0.71
Thermo Fisher Scientific Inc. 1.01 1.04 1.02 0.93 0.90 0.88 0.90 0.86

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Equity turnover = (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020) ÷ Total Illumina stockholders’ equity
= (1,108 + 1,126 + 1,093 + 953) ÷ 10,593 = 0.40

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Illumina Inc. equity turnover ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.